Vaccination for Recovered Inpatients With COVID-19 (VATICO)

Covid19 Clinical Trial

Official title:

SARS-CoV-2 Vaccination Strategies in Previously Hospitalized and Recovered COVID-19 Patients

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04969250
• Other study ID #: 016 / VATICO
• Status: Completed
• Phase: Phase 4
• Start date: August 25, 2021
• Est. completion date: December 21, 2022

Study information

• Verified date: March 2024
• Source: National Institute of Allergy and Infectious Diseases (NIAID)
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

In this Phase 4, open-label trial, participants of the ACTIV-3/TICO clinical trial at selected sites who received certain pre-specified blinded investigational agents or placebo as part of that trial, and who have since achieved sustained recovery, and who are still [TICO assignment] blinded and who are still within 28 to 90 days after initial TICO randomization, will be randomized in this 2x2 factorial design to one of four groups: (i) immediate versus 12 week deferral of first dose administration and also (ii) one dose only, versus two doses to be given 4 weeks apart of the Moderna mRNA-1273 or the Pfizer BNT162b2 vaccine (mRNA vaccines).

Choice of Moderna or Pfizer vaccine is determined based on availability at the site. The choice is individual, although participants vaccinated twice should receive the same type of vaccine for both injections. The primary objectives of this 2x2 factorial design are (i) to estimate the difference in neutralizing antibody (NAb) response to the mRNA vaccine from baseline to Week 48 among participants vaccinated early versus deferred, and (ii) to estimate the difference in NAb response to this vaccine among participants vaccinated once versus twice. The primary analyses will be carried out in participants randomized to placebo in TICO. Analyses will also be carried out for those who receive the investigational agent(s) studied in TICO.

A key secondary objective is to ascertain the effect, if any, of SARS-CoV-2 monoclonal antibodies, and other interventions that have been studied in hospitalized COVID-19 subjects, on natural and vaccine-induced immunity.

Participants will remain blinded to the interventions received in the ACTIV-3/TICO study, however allocation to the timing of vaccination and to one or two vaccinations in this (VATICO) study is not blinded.

Description:

In this Phase 4 trial, participants in the TICO master protocol who received certain pre-specified blinded investigational agents or matched placebos will be offered enrollment, with the understanding that this will require 2X2 randomized assignment of the timing and of the number of mRNA SARS-CoV-2 vaccinations to be received, via publicly-available mRNA SARS-CoV-2 vaccination sites or via other routes, in keeping with the 4 specified study arm assignments.

This will address the objective of evaluating if the vaccine is best administered early or deferred after recovery, and whether one injection provides comparable immune response to a two-injection course of vaccination. Participants (as well as the protocol team) will remain blinded to the interventions studied in TICO. Allocation to timing of vaccination and to one or two vaccinations is not blinded. Participants will be offered enrollment in this protocol at the Day 28 or Day 90 visits in TICO, or anytime between these visits.

Participants will have blood collected for research purposes at the time of enrollment and at Weeks 12, 24, and 48.

The study vaccine and regimen will not be blinded; there will be be no 'dummy/placebo' vaccine administered. Vaccines are expected to be made available either through the study directly, or through a reliable public vaccination program using vaccine available per the local regulatory mechanism (e.g., currently under Emergency Use Authorization (EUA) for the United States) or via other routes in case such local mechanisms are not available.

Participants will be equally allocated to 4 groups to inform each of two vaccine strategies:

• One injection versus two (for the immediate and deferred groups)

• Immediate versus deferred (for one and two vaccinations)

Hence, the outcome of the randomization will lead to one of the four following vaccination strategies for each study participant:

I1 - Immediate, one dose: vaccination at study entry only I2 - Immediate, two doses:

vaccination at study entry and Week 4 D1 - Deferred, one dose: vaccination at Week 12 only D2

• Deferred, two doses: vaccination at Week 12 and Week 16

Randomization will be stratified by study site and by randomization assignment in TICO for certain pre-specified investigational agents or their matching placebo.

When addressing the two co-primary objectives, the following groups are combined:

• Immediate vs deferred vaccine: groups I1 and I2 versus D1 and D2

• One versus two vaccinations: groups I1 and D1 versus I2 and D2

Similar comparisons will be made separately for each of the two principal TICO arms, i.e., for those assigned to one of the investigational agents and for those assigned to the matching placebo. Both of these comparisons are protected by the randomization in the present study.

Given the factorial design, whether there is an interaction of one factor (timing of vaccination) with the other factor (number of doses) will need to be assessed although the study is not fully powered for this evaluation.

A key secondary objective is to address whether the investigational agent studied in TICO (versus matching placebo) is affecting the primary outcome in this protocol. Of note, this comparison may not always be protected by randomization, as there may be differential inclusion in this protocol between those receiving the investigational agent in TICO and those receiving its matching placebo. This is more likely to be the case if the investigational agent is demonstrated to affect the chance of achieving sustained recovery.

The primary endpoint, immune response specific to the vaccination received, will be assessed at Week 48. Participants will have blood collected at time of enrollment, and at Weeks 12, 24 and 48 after study entry. Approximately 640 participants will be recruited. The total sample size will depend on how many investigational agents/placebo are evaluated in ACTIV-3/TICO.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 66
• Est. completion date: December 21, 2022
• Est. primary completion date: December 21, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Participating in the ACTIV-3/TICO trial and received a selected blinded investigational agent, or placebo for that agent, at selected sites.

• Willingness to strictly adhere to the randomly allocated dosage number and schedule for vaccine administration.

• Participant is between Day 28 and Day 90 TICO visits inclusive at time of randomization.

• At time of screening for this study, has experienced sustained recovery (i.e., the primary endpoint in TICO) for at least two consecutive weeks, i.e. having returned uninterrupted to the person's premorbid living facility (or equivalent) for at least 2 consecutive weeks.

• Ability and willingness of participant (or legally authorized representative) to provide informed consent prior to initiation of any study procedures.

Exclusion Criteria:

• Receipt of a SARS-CoV-2 (COVID-19) vaccine after enrollment into TICO. Participants who received a SARS-CoV-2 vaccine prior to enrollment in TICO may be enrolled in this study.

• Known allergy to any component of the study eligible vaccine(s).

Related Conditions & MeSH terms

• COVID-19
• Covid19

Intervention

Biological:
• Moderna mRNA-1273 COVID-19 vaccine
100 µg intramuscular injection
• Pfizer BNT162b2 COVID-19 vaccine
30 µg intramuscular injection

Locations

Country	Name	City	State
Nigeria	Institute of Human Virology-Nigeria (Site 612-601), International Research Center of Excellence, Cadastral Zone COO Plot 62, after BAZE University, off CITEC Road	Abuja
Singapore	Tan Tock Seng Hospital (Site 612-201), National Center for Infectious Diseases (NCID), 11 Jalan Tan Tock Seng	Singapore
Spain	Hospital Clinic de Barcelona (Site 626-004), Carrer de Villaroel 170	Barcelona
Spain	Hospital Universitari Germans Trias i Pujol (Site 626-003) Carretera de Canyet, s/n	Barcelona
Spain	Hospital Universitari Vall d'Hebron (Site 626-033), Passeig Vall Hebron, 119-129	Barcelona
Spain	Hospital Universitari Arnau de Vilanova (Site 026-035), Institut de Recerca Biomèdica de Lleida, Av. Rovira Roure, 80	Lleida
Spain	Hospital General Universitario Gregorio Marañón (Site 626-001), Servicio de Inmunología Clínica, Departamento de Medicina Interna, Dr. Esquerdo, 46	Madrid
Switzerland	University Hospital Zurich (Site 621-201), Raemistrasse 100	Zürich
Uganda	MRC/UVRI & LSHTM Uganda Research Unit (Site 634-601), Plot 51-59 Nakiwogo Road, P.O. Box 49	Entebbe
Uganda	Gulu Regional Referral Hospital (Site 634-603), P.O. Box 160	Gulu
Uganda	Makerere University Lung Institute (634-604), Mulago National Referral Hospital	Kampala
Uganda	St. Francis Hospital, Nsambya (Site 634-607), Nsambya Road Nsambya Hill, P.O. Box 7146	Kampala
Uganda	Lira Regional Referral Hospital (Site 634-605), Plot 9/19, 21-41 Ngetta Road Police Road	Lira
Uganda	Masaka Regional Referral Hospital (Site 634-606), MRC/UVRI and LSHTM Uganda Research Unit, Plot 6 Circle Road, PO Box 556	Masaka
United States	CHRISTUS Spohn Shoreline Hospital (Site 080-001), 600 Elizabeth Street	Corpus Christi	Texas
United States	Parkland Health and Hospital Systems (Site 084-002), James Aston Ambulatory Care Center - Clinical Research Unit, 5303 Harry Hines Blvd., Ste U-9.300	Dallas	Texas
United States	UT Southwestern Medical Center (Site 084-001), 1936 Amelia Court, 2nd Floor	Dallas	Texas
United States	Public Health Institute at Denver Health (Site 017-004), 660 Bannock Street	Denver	Colorado
United States	Duke University Hospital (Site 301-006), 2301 Erwin Road	Durham	North Carolina
United States	Cedars-Sinai Medical Center (Site 208-002), 8700 Beverly Blvd	Los Angeles	California
United States	Minneapolis VA Medical Center (Site 105-001), 1 Veterans Drive	Minneapolis	Minnesota
United States	Rhode Island Hospital (Site 080-036), 593 Eddy St.	Providence	Rhode Island
United States	The Miriam Hospital (Site 080-039), 164 Summit Ave.	Providence	Rhode Island
United States	Salem VA Medical Center (Site 074-014), 1970 Roanoke Blvd.	Salem	Virginia
United States	San Francisco VAMC (Site 074-002), 4150 Clement Street	San Francisco	California
United States	Stanford University Hospitals & Clinics (Site 203-003), Stanford University, School of Medicine, 300 Pasteur Dr., Grant Bldg, Room S011	Stanford	California
United States	Hillsborough County Health Department, University of South Florida (Site 032-001), 1105 E. Kennedy Blvd.	Tampa	Florida
United States	Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center (Site 066-002), 1124 W. Carson St., CDCRC	Torrance	California
United States	Washington DC VA Medical Center (Site 009-004), 50 Irving Street, NW.	Washington	District of Columbia
United States	Wake Forest Baptist Health (Site 210-001), Medical Center Boulevard	Winston-Salem	North Carolina

Sponsors (12)

Lead Sponsor

Collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

AIDS Clinical Trials Group, Cardiothoracic Surgical Trials Network, International Network for Strategic Initiatives in Global HIV Trials (INSIGHT), Kirby Institute, Medical Research Council, National Heart, Lung, and Blood Institute (NHLBI), Prevention and Early Treatment of Acute Lung Injury, University of Copenhagen, University of Minnesota, US Department of Veterans Affairs, Washington D.C. Veterans Affairs Medical Center

Countries where clinical trial is conducted

United States,  Nigeria,  Singapore,  Spain,  Switzerland,  Uganda, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Ratio of 48-Week to Baseline Neutralizing Antibody (NAb) Levels	Change in antibody level as measured by ratio of follow-up to baseline level	Pre-vaccination baseline and 48 weeks post-vaccination
Secondary	Ratio of 12-Week to Baseline Neutralizing Antibody (NAb) Levels	Change in antibody level as measured by ratio of follow-up to baseline level	Pre-vaccination baseline and 12 weeks post-vaccination
Secondary	Ratio of 24-Week to Baseline Neutralizing Antibody (NAb) Levels	Change in antibody level as measured by ratio of follow-up to baseline level	Pre-vaccination baseline and 24 weeks post-vaccination
Secondary	Number of Deaths	Count of Deaths	Through Week 24 after enrollment
Secondary	Number of Serious Adverse Events (SAEs)	Count of SAEs	Through Week 24
Secondary	Number of Patients Non-adherent to 2nd Dose	Number of participants assigned a 2nd vaccine dose who did not receive it for any reason	Second vaccine doses were due at 4 and 16 weeks after randomization in Arm 2 and 4, respectively
Secondary	Number of Patients Non-adherent to Assigned Treatment Strategy	Number of participants who received more or less vaccine than assigned, or who received vaccines at different time points than assigned	Vaccine doses were due through 16-weeks post-randomization; participants were followed for vaccination status through 48 weeks post-randomization
Secondary	Percent of Patients With >=4-fold Difference in NAb	Percentage of participants with >=4-fold change in NAb from baseline to 48 weeks	Pre-vaccination baseline and 48 weeks post-vaccination

External Links

•   A Participant's Guide to Clinical Trials (NIAID)
•   CDC (Centers for Disease Control and Prevention): Coronavirus (COVID-19) website
•   Clinical Trials at NIAID
•   FDA Safety Alerts and Recalls
•   Find a Clinical Trial
•   National Institute for Allergy and Infectious Diseases (NIAID)
•   NIH COVID-19 treatment guidelines
•   WHO COVID-19 treatment guidelines